Detalhe da pesquisa
1.
Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens.
PLoS Pathog
; 19(6): e1011485, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37384813
2.
Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques.
Vaccines (Basel)
; 12(4)2024 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38675751
3.
Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.
Vaccines (Basel)
; 11(5)2023 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37243081
4.
Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen.
Emerg Microbes Infect
; 12(2): 2251595, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37649434
5.
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.
Nat Med
; 26(6): 932-940, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32393800
6.
High level of sequence variation in the 3' noncoding region of Japanese encephalitis viruses isolated in Korea.
Virus Genes
; 24(1): 21-7, 2002.
Artigo
Inglês
| MEDLINE | ID: mdl-11928985